Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Myeloma Triplet Does Not Worsen Health-Related Quality of Life

      July 8, 2019
      By Brielle Benyon
      Article

      Now that patients have more drug options to treat myeloma, quality of life is becoming more important, said one expert.

      Health-related quality of life is an important factor to consider when treating patients with multiple myeloma. Now, there are more treatment regimens and combinations than ever, and it is vital that healthcare teams understand how these drugs impact patients in their day-to-day, explained David S. Siegel, MD, PhD.

      Siegel, the chief of the myeloma division at the John Theurer Cancer Center, was recently involved in a study that examined health-related quality of life for patients with relapsed or refractory myeloma who were taking the 3-drug regimen of pomalidomide (Pomalyst), low-dose dexamethasone, and daratumumab (Darzalex) after lenalidomide (Revlimid) treatment.

      “It's nice to know that we're not only able to control the disease way better than we used to, but that we now have tools that don't slam the patient while we're doing that,” Siegel said in a recent interview with OncLive, a sister publication of Oncology Nursing News.

      Oncology Nursing News: Can you provide insight into how health-related quality of life has become an important aspect of myeloma treatment?

      Siegel: We spent many decades without any new drugs in multiple myeloma, so quality of life was unfortunately largely ignored because we were just desperately looking for drugs that had activity.

      Now, all of a sudden, we have a multitude of drugs. Thankfully, many of them are very effective, so it becomes a question as to, 'What is the impact of these drugs on quality of life?' This [3-drug regimen] is a very important combination in myeloma right now, and this is the first attempt to look at quality of life related to the administration of daratumumab, pomalidomide, and dexamethasone.

      Can you give a brief background on this research, as well as the findings?

      Daratumumab and pomalidomide are 2 of the most important drugs that have come along in the last decade for the management of myeloma. The combination of daratumumab, pomalidomide, and dexamethasone is very important.

      But one of the major issues in multiple myeloma is this impression that you have to change classes of drugs. So [lenalidomide] is the most widely used drug in myeloma. Pomalidomide is a very similar molecule to [lenalidomide], so there's a lot of concern over whether you can go from one to the other. The overarching finding of this trial is that you can do it both safely and with a significant degree of efficacy.

      Now, we have a great regimen, we know where we can use it, but what impact does it have on quality of life? This is the first assessment of that, and it does it in a unique setting in that this is very early in the treatment of myeloma, so most of the patients are still very healthy. When you're very sick from the myeloma, just controlling the myeloma is enough to improve the quality of life fairly significantly. But these are patients who have not been dramatically compromised by the myeloma itself. So, you expect this 3-drug combination, particularly one including corticosteroids, to have a negative impact on patients' functionality and perception of quality of life. But that wasn’t the case.

      We used a number of tools. There's a visual scoring from 1 to 100 (of) ‘How do you feel?’ The patients came in feeling fairly well, with scores of around 90, and they came out of the trial with scores of about 90. And then you have this 5-question panel of 'How are you interacting with your friends? How mobile are you? What impact does this have on you psychologically? How does it impact your daily activities?' The bottom line is it was basically stable across all those parameters. If there was a change, it was to have slight improvements. So, you have a 3-drug combination that is highly effective and didn't negatively impact on the patients' quality of life. In fact, they had improved quality of life, despite the fact that they came into this study, so it's interesting.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      A panel of 3 experts on CML
      A panel of 3 experts on CML
      Related Content

      Photo of a woman undergoing radiation therapy

      What Should Oncology Nurses Know About Biology-Guided RT?

      Bridget Hoyt
      August 8th 2025
      Article

      The Vitals

      Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

      Lindsay Fischer
      August 8th 2025
      Podcast

      Graphic of malignant B cells

      Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCL

      Chris Ryan
      August 8th 2025
      Article

      Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

      Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

      Lindsay Fischer
      August 8th 2025
      Podcast

      Graphic depicting red blood cells

      Generic Ibrutinib Tablet Given Tentative FDA Approval in CLL/SLL, WM

      Bridget Hoyt
      August 8th 2025
      Article

      Photo of a main holding his lower back in pain with a graphic of a kidney overlaying

      Opinion: IV Magnesium May Help Prevent Cisplatin-Induced AKI

      Amanda Brink, DNP, APRN, FNP-BC, AOCNP
      August 8th 2025
      Article
      Related Content

      Photo of a woman undergoing radiation therapy

      What Should Oncology Nurses Know About Biology-Guided RT?

      Bridget Hoyt
      August 8th 2025
      Article

      The Vitals

      Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

      Lindsay Fischer
      August 8th 2025
      Podcast

      Graphic of malignant B cells

      Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCL

      Chris Ryan
      August 8th 2025
      Article

      Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

      Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

      Lindsay Fischer
      August 8th 2025
      Podcast

      Graphic depicting red blood cells

      Generic Ibrutinib Tablet Given Tentative FDA Approval in CLL/SLL, WM

      Bridget Hoyt
      August 8th 2025
      Article

      Photo of a main holding his lower back in pain with a graphic of a kidney overlaying

      Opinion: IV Magnesium May Help Prevent Cisplatin-Induced AKI

      Amanda Brink, DNP, APRN, FNP-BC, AOCNP
      August 8th 2025
      Article

      Latest Conference Coverage

      PI3K and AKT Inhibitor Toxicity Advice From a Breast Cancer Expert

      Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCL

      Q&A: Nursing Considerations From Immune Cell Effector Therapy Experts

      Proactive Rash Management Vital for PI3K, AKT Inhibition in Breast Cancer

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.